
Sarepta Reports Q3 2025 Results, Completes ESSENCE Study
Sarepta Completes ESSENCE Confirmatory Trial for AMONDYS 45 and VYONDYS 53, Reports Encouraging Trends and Strong Pipeline Momentum in Q3 2025 Sarepta Therapeutics, Inc a global leader in precision genetic medicines for rare diseases, announced the completion of ESSENCE, its…












